Loading...
•
Dec 31, 2024
Precigen Q4 2024 Earnings Report
Precigen reported its Q4 2024 results, completing a year focused on advancing PRGN-2012 toward commercialization and maintaining financial discipline.
Key Takeaways
In Q4 2024, Precigen reported $1.19 million in revenue and a net loss of $19.73 million, with an EPS of -$0.06. The company continued preparations for the anticipated commercial launch of PRGN-2012 in 2025 and successfully extended its cash runway into 2026.
Q4 revenue reached $1.19 million.
Q4 net loss was $19.73 million, with EPS of -$0.06.
The company completed pre-BLA meetings and is aligned with the FDA for PRGN-2012 submission.
Cash, cash equivalents, and investments totaled $97.9 million at year-end 2024.
Precigen
Precigen
Precigen Revenue by Segment
Revenue by Segment
Product revenues Revenue
CapyFin.comService revenues Revenue
CapyFin.comOther revenues Revenue
CapyFin.com Forward Guidance
Precigen expects to achieve FDA approval and launch PRGN-2012 in 2025, expanding its reach and revenue base.
Positive Outlook
- BLA submission for PRGN-2012 planned and aligned with FDA.
- Cash runway extended into 2026.
- Strong clinical trial data supporting PRGN-2012 efficacy.
- Active preparations for commercial and manufacturing scale-up.
- Estimated market opportunity of 27,000 adult RRP patients in the US.
Challenges Ahead
- Continued quarterly net losses.
- Revenue remains low prior to commercial launch.
- Significant impairment charges recorded in 2024.
- Dependence on regulatory milestones for growth.
- High R&D expenses continue to weigh on financials.
Revenue & Expenses
Visualization of income flow from segment revenue to net income